Objective-To present results from the NHS breast screening programme (NHS-BSP) from 1994 through to 1999 and to examine the extent to which interim targets are being achieved. Methods-Data were collated from all screening programmes in the UK on standard statistical returns. Performance of the screening programme was evaluated using calculated targets based on comparison with the Swedish two counties (STC) randomised controlled trial. Results-In the early years of screening (1988-1993), the NHS programme was detecting more DCIS but considerably less invasive cancers than expected, based on the STC trial. Since the screening year 1993/94 (1 April to 31 March) the standardised detection ratio (SDR) measure of the detection of invasive cancers has increased by 36% from 0.83 to 1.13. The SDR has been greater than 1 since 1996/97 suggesting that the NHSBSP has only been screening as eYciently as the STC trial since this date. Uptake for screening has been relatively stable over time at approximately 75%. Conclusions-The NHSBSP has made considerable advances in performance since its inception in 1988 and screening uptake and age standardised invasive cancer detection rates are (by 1999) well in excess of targets. The early years of screening were characterised by good uptake but a low sensitivity for the detection of invasive cancers. It is anticipated that the screening programme will have an increasing impact on breast cancer mortality, particularly in the 55-69 year age group over the coming years.
The UK breast screening programme (NHS-BSP) was established in 1988 on the basis of the Forrest report. 1 Results from the programme from 1990 to 1993 have been published previously. 2 The earlier results suggested that the majority of programmes were detecting more than the (then) target rate of five cancers per 1000 women but that detection of invasive cancers less than 10 mm in diameter might be low. While 79% of programmes were achieving a prevalent screening cancer detection rate of greater than 5 per 1000, only 30% were detecting a small (<10 mm) invasive cancer detection rate greater than 1.5 per 1000. For incident screens during these early years, fewer programmes were meeting the target cancer detection rate of 3.5 per 1000. At that time information on the size of all invasive cancers was incomplete. In 1995 two papers were published by the East Anglian region 3 and North Western region 4 showing higher than expected interval cancer rates, the former suggesting this might be due to poor sensitivity for small invasive cancers.
It is now clear that the early target detection rate of five cancers per 1000 women screened was too crude a measure, taking into account neither the age distribution of the women being screened nor the type of cancers being detected. Updated targets for cancer detection have since been published addressing these issues. 5 In this paper we present the results from the NHSBSP for the six screening years from 1 April 1993 to 31 March 1999. The results concentrate on uptake rate, referral rate for further investigation, cancer detection rate, and invasive cancer detection rates. The results are subdivided by prevalent (first) screen and incident (subsequent) screens.
Detailed statistics are published annually by the NHSBSP (NHSBSP annual review) and the Department of Health (Statistical Bulletin) and it is not the purpose of this paper to replicate such statistics. "Monitoring statistics" can be misleading as factors such as the age distribution of women attending for prevalent screens has changed over the years. For example, in the beginning of the screening programme all women aged 50-64 years were invited for screening (mean age 57.5 years) whereas in the last few years women invited for the first time are now aged 50, 51, or 52 years (mean age 51.5). Measurements such as cancer detection rate or interval cancer rates can be confounded by age. This paper will provide information over the last six screening years in a form where the changes in performance of the NHSBSP over time can be readily examined.
Methods
The standard statistical returns from the 95 individual screening programmes in England, Scotland, Northern Ireland, and Wales are collected and analysed by the Cancer Screening Evaluation Unit. Over the period in question, the statistical returns have been changed to provide more detailed information but this has also resulted in some minor problems in comparing data across years. The returns in use since 1994/95 hold similar data and are largely compatible. The return used in 1993/94 is different, rendering evaluation of data over time more diYcult. For example, in 1993/94 <10 mm was used as the smallest size category but from 1994/95 onwards <10 mm was used, causing problems of comparability because sizes near 10 mm are commonly rounded by pathologists to 10 mm exactly. This results in a large number of 10 mm tumours but fewer 9 mm or 11 mm tumours, despite the fact that rounding should be to the nearest 1 mm. In addition, for 1993/94 returns, results for all prevalent or incident screens are presented together, whereas from 1994/5 onwards prevalent and incident screens are divided into two subgroups.
In this paper, data have been presented only if they are considered comparable over time. For example, the crude cancer detection rate for prevalent screens only is presented for women invited for the first time aged 50-54 years in order to avoid confounding by age. For subsequent screens, confounding by age is less of a problem and rates are presented for women aged 50-64.
Detection rates of invasive cancers are presented using the age standardised detection ratio (SDR). 6 The expected rates within each age group are calculated based on parity with the Swedish two counties (STC) randomised controlled trial, 7 an SDR of 1 indicating parity. Tables 1 and 2 show uptake and referral rates for both prevalent (first) and incident (subsequent) screens. Uptake of screening has remained fairly stable over the six years, at around 76% for first invitation to screening (women aged 50-54) and 90% for subsequent invitations to women previously screened (women aged 50-64). In women who initially refused an invitation to screening, uptake is of the order of 20% while women who are being invited more than five years after their last screen ("lapsed attenders") have an uptake of around 60%. The NHSBSP defines overall uptake as the percentage of women aged 50-64 invited to all prevalent and routine incident screens. For 1998/99 there were 1 660 031 such invited women of whom 1 260 082 were screened, an uptake of 76%.
Results

UPTAKE AND REFERRAL RATES
Referral rates for assessment of abnormalities seen at the initial screen have increased with time from 7.0% in 1993/94 to 8.3% in 1998/99 for prevalent screens, and from 3.1% to 3.8% for incident screens. For the screening year 1998/99, the referral rates for individual programmes for prevalent screens varied from 2.4% to 15.4% with a mean of 8.2% (SD 2.5%). Of the 95 individual programmes, 34 (36%) had referral rates within the target of less than 7% and 70 (74%) were within the minimum standard of 10%. For incident screens the individual referral rates varied from 1.5% to 7.2% with a mean of 3.8% (SD 1.1%), of which 79 (83%) programmes had referral rates within the target of 5% and 94 (99%) were within the minimum standard of 7%. Tables 1 and 2 also show cancer detection rates and positive predictive values (PPV). For both prevalent and incident screens, a small increase was seen in the PPV of referral-that is, the Table 5 shows the SDRs for prevalent and incident screens. The SDR has increased by 36% from 0.83 to 1.13 over the period 1993/94 to 1998/99. In 1993/94 the SDR of 0.83 corresponded to an estimated 898 invasive cancers less than the expected number, assuming parity with the STC trial. By 1998/99 this had changed to an SDR of 1.13 corresponding to an additional 680 invasive cancers being detected above the expected number. For the screening year 1998/99, the 95 individual screening programmes had a mean SDR of 1.11 (SD 0.18) with a range of 0.61-1.63. Of the 95 programmes, 76 (80%) achieved an SDR above 1. Figure 1 shows the SDR from 1993/94 to 1998/99 for prevalent and incident screens separately and combined. Prevalent screen SDRs exceeded 1 from 1995/ 96, incident screens from 1998/99, and the combined SDR from 1996/97. These results show that the NHSBSP has only been screening as eYciently as the STC in the last few years.
CANCER DETECTION RATES
NON-OPERATIVE DIAGNOSIS
In recent years more cancers have been diagnosed definitively by cytology or core biopsy, resulting in fewer women undergoing open biopsy. For the screening year 1998/99, of the 88 programmes in the NHSBSP (excluding Scotland for which no comparable data are available) 11 (12.5%) diagnosed more than 90% of cancers non-operatively, and 66 (75%) diagnosed more than 70% of cancers nonoperatively. The target non-operative diagnosis rate set by the NHSBSP is now 70% and the overall national rate is 80%.
Discussion
These data suggest that the performance of the NHSBSP has improved considerably since the beginning of screening in 1988. The early years of screening were characterised by a poor sensitivity for invasive cancers leading to high interval cancer rates. 3 4 The major increases in sensitivity which have occurred since these early years should lead to much lower interval cancer rates when comparing rates by five year age bands. Some form of age standardisation is required because women undergoing prevalent screens in the early years of screening were aged 50-64, but are now either 50, 51, or 52 years, and interval cancer rates are highly dependent on age. An inverse relationship between cancer detection (as measured by the SDR) and interval cancer rates has been shown using data from the South West Thames Region. 9 The increases in screening sensitivity have been the result of a number of improvements to the programme. Firstly, the policy for prevalent screening was changed in August 1995 from one view (mediolateral oblique) mammography to two views (mediolateral oblique+craniocaudal) following the results of a randomised controlled trial. 10 Secondly, the film density has been optimised at 1.4 D to 1.8 D, again on the basis of published research. 11 Thirdly, quality assurance teams have investigated individual programmes with low detection rates, often resulting in major improvements in sensitivity. Fourthly, the skill base necessary to achieve a consistent high performance has been realised over the first decade of screening. By 1998/99 the age standardised invasive cancer detection rate at prevalent screens is now an estimated 29% higher than that achieved by the STC trial and 13% higher for prevalent and incident screens combined. Before 1996/97 the invasive cancer detection rate was below that achieved by the STC trial and prior to 1994/95 well below. The final mortality reduction resulting from screening sensitivities before 1994/95 would be expected to be well below that achieved by the STC trial. In contrast, the recent screening performance would suggest that a final mortality reduction in excess of that achieved by the STC is likely but it will be at least 2005-2010 before this is seen in national statistics. The impact of the NHSBSP on national mortality statistics is likely to be a gradual reduction between 1992 and 2010 rather than any sharp decrease: a 25% mortality reduction achieved over nearly 20 years corresponding to, on average, about 1% or 2% per year, mostly in the age group 55-69.
The quantity and quality (data accuracy and completeness) of information provided on the returns has improved over the years, and this has enabled the performance of both individual programmes and the NHSBSP as a whole to be examined in greater detail. Future returns may include additional information such as grade and nodal status, although the main indicator of the performance of the NHSBSP remains invasive cancer detection rates and size distributions.
Cancer detection rates have increased steadily for both prevalent and incident screens, and this has led to an increase in PPV despite increasing referral rates. Detection rates of DCIS have also increased over time, possibly being influenced by the increasing use of core biopsy. The high SDRs in recent years suggest that the NHSBSP is currently performing better than the STC trial, particularly for prevalent screens. However, without full information on interval cancers this cannot be confirmed. At present, variation in completeness of ascertainment of data on interval cancers between regions precludes analysis of national rates.
The NHSBSP is now diagnosing the vast majority of women with breast cancer by cytology or core biopsy rather than open biopsy. All of these indicators show that the NHSBSP has made a steady progressive improvement in screening eYciency since its inception.
Of continuing interest is the variation in referral rates of individual programmes and the balance between referral rates and cancer detection rates. Programmes which aim to refer as few women as possible may do so at the expense of a reduced cancer detection rate while those who refer high numbers of women for assessment may achieve a high cancer detection rate at the expense of a lower PPV of referral. The characteristics of optimum performance of screening in terms of a high cancer detection rate, low referral rate, and a high PPV will be examined in detail in a further paper.
The Forrest report acknowledged the need for the NHSBSP to respond to new developments and information. The major improvements over the past decade relate both to the quality of information available and to improvements in film reading and assessment. Future developments may include the use of computer aided detection, changes in the age group of women invited to screening, and the use of two views for all screens. At the same time staV shortages and the increasing number of women in the eligible age group over the next 20 years will place great pressures on the service.
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